Literature DB >> 4578640

Cholestyramine in type II hyperlipoproteinemia. A double-blind trial.

R I Levy, D S Fredrickson, N J Stone, D W Bilheimer, W V Brown, C J Glueck, A M Gotto, P N Herbert, P O Kwiterovich, T Langer, J LaRosa, S E Lux, A K Rider, R S Shulman, H R Sloan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4578640     DOI： 10.7326/0003-4819-79-1-51

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  8 in total

Review 1.  A comparative review of the adverse effects of treatments for hyperlipidaemia.

Authors:  A Steiner; B Weisser; W Vetter
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

Review 2.  An overview of lipid-lowering drugs.

Authors:  D R Illingworth
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Low-density lipoprotein plasmaphaeresis with and without lovastatin in the treatment of the homozygous form of familial hypercholesterolaemia.

Authors:  J Thiery; A K Walli; G Janning; D Seidel
Journal:  Eur J Pediatr       Date:  1990-07       Impact factor: 3.183

Review 4.  Effects of dyslipidaemia on monocyte production and function in cardiovascular disease.

Authors:  Mohammed Shamim Rahman; Andrew J Murphy; Kevin J Woollard
Journal:  Nat Rev Cardiol       Date:  2017-03-16       Impact factor: 32.419

5.  [Drug treatment of primary hyperlipoproteinemia (author's transl)].

Authors:  G Klose; R Mordasini; G Middelhoff; J Augustin; H Greten
Journal:  Klin Wochenschr       Date:  1978-02-01

6.  [Relation between serum lipoprotein metabolism and biliary lipid metabolism].

Authors:  O Leiss; K von Bergmann
Journal:  Klin Wochenschr       Date:  1983-06-15

7.  Treatment of the arthropathy of familial hypercholesterolaemia.

Authors:  G J Carroll; C E Bayliss
Journal:  Ann Rheum Dis       Date:  1983-04       Impact factor: 19.103

8.  Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine.

Authors:  E Hagen; H Istad; L Ose; E Bodd; H M Eriksen; V Selvig; J M Bard; J C Fruchart; M Borge; M C Wolf
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.